Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Common Equity (2020 - 2025)

Journey Medical (DERM) has disclosed Common Equity for 6 consecutive years, with $25.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 137.03% year-over-year to $25.9 million, compared with a TTM value of $25.9 million through Sep 2025, up 137.03%, and an annual FY2024 reading of $20.1 million, down 1.38% over the prior year.
  • Common Equity was $25.9 million for Q3 2025 at Journey Medical, up from $19.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $42.0 million in Q4 2021 and bottomed at -$11.7 million in Q3 2021.
  • Average Common Equity over 5 years is $17.2 million, with a median of $17.4 million recorded in 2023.
  • The sharpest move saw Common Equity tumbled 271.61% in 2021, then skyrocketed 225800.0% in 2024.
  • Year by year, Common Equity stood at $42.0 million in 2021, then crashed by 59.61% to $17.0 million in 2022, then increased by 19.83% to $20.3 million in 2023, then decreased by 1.38% to $20.1 million in 2024, then rose by 29.04% to $25.9 million in 2025.
  • Business Quant data shows Common Equity for DERM at $25.9 million in Q3 2025, $19.2 million in Q2 2025, and $21.5 million in Q1 2025.